O14-1 Pembrolizumab + chemotherapy in Japanese patients with persistent, recurrent, or metastatic cervical cancer: KEYNOTE-826

Kan Yonemori,Shin Nishio,Tomoka Usami,Shinichiro Minobe,Mayu Yunokawa,Takashi Iwata,Aikou Okamoto,Yoichi Aoki,Hiroaki Itamochi,Munetaka Takekuma,Kenichi Harano,Keiko Yamamoto,Hiroyuki Ugai,Cumhur Tekin,Sarper Toker,Nicoletta Colombo,Keiichi Fujiwara,Kosei Hasegawa

Annals of Oncology（2022）

引用 0|浏览4

暂无评分

摘要

Pembrolizumab (pembro) + chemotherapy (chemo) ± bevacizumab (bev) prolonged PFS and OS vs chemo in patients (pts) with persistent, recurrent, or metastatic cervical cancer in the protocol-specified first interim analysis of the global, phase 3, randomized, double-blind, placebo-controlled KEYNOTE-826 (NCT03635567) study. We present outcomes in pts enrolled in Japan in KEYNOTE-826.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要